Article
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jul 2016
Bouffet Eric, Larouche Valérie, Campbell Brittany B, Merico Daniele, de Borja Richard, Aronson Melyssa, Durno Carol, Krueger Joerg, Cabric Vanja, Ramaswamy Vijay, Zhukova Nataliya, Mason Gary, Farah Roula, Afzal Samina, Yalon Michal, Rechavi Gideon, Magimairajan Vanan, Walsh Michael F, Constantini Shlomi, Dvir Rina, Elhasid Ronit, Reddy Alyssa, Osborn Michael, Sullivan Michael, Hansford Jordan, Dodgshun Andrew, Klauber-Demore Nancy, Peterson Lindsay, Patel Sunil, Lindhorst Scott, Atkinson Jeffrey, Cohen Zane, Laframboise Rachel, Dirks Peter, Taylor Michael, Malkin David, Albrecht Steffen, Dudley Roy W R, Jabado Nada, Hawkins Cynthia E, Shlien Adam, Tabori Uri
Abstract excerpt
PURPOSE: Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome often resulting in GBM characterized by a high mutational burden. Evidence suggests that high mutation and neoantigen loads are associated with response to immune checkpoint inhibition. PATIENTS AND METHODS: We performed exome sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.